Literature DB >> 10969343

Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay.

J M Achkar1, X H Wang, P Nyambi, M K Gorny, S Zolla-Pazner, J C Bandrés.   

Abstract

To be successful with strategies involving passive immunization or the generation of neutralizing antibodies against HIV, it is crucial that we improve our understanding of the process of antibody-mediated HIV neutralization. We have used a neutralization assay based on polymerase chain reaction (PCR) that is more rapid and sensitive than the conventional p24 neutralization assay based on enzyme-linked immunosorbent assay (ELISA). PCR assays permit measurement of the number of infectious events and can detect small amounts of HIV-1 only a few days postinfection. In these studies, the human anti-V3 monoclonal antibody 694/98-D was used to neutralize the infectivity of the laboratory isolate HIVIIIB for CEM-SS cells. 8E5/LAV cells, which contain a single integrated copy of proviral DNA per cell, served as a standard to determine the amount of HIV-1 copies in infected CEM-SS cells. Evaluation of antibody-mediated neutralization was possible at 2 to 3 days postinfection, at a time when p24 readouts were not conclusive. We achieved >95% neutralization of HIVIIIB, and of its molecular clone HXB2, using the monoclonal antibody 694/98-D. This degree of neutralization is probably highly significant in vivo. Nevertheless, a small amount of both HIVIIIB and HXB2 ( approximately 5%) escapes neutralization and can consistently be detected after a few days by this sensitive assay. Experiments with different anti-HIV monoclonal antibodies and viruses showed that the assay could be applied to anti-V3 as well as anti-CD4 binding domain antibodies as well as HIV laboratory strains or primary isolates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969343     DOI: 10.1097/00126334-200007010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  4 in total

1.  LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission.

Authors:  C E Hioe; P C Chien; C Lu; T A Springer; X H Wang; J Bandres; M Tuen
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA).

Authors:  Catarina E Hioe; Michael Tuen; Gaia Vasiliver-Shamis; Yelina Alvarez; Kathleen C Prins; Sagarika Banerjee; Arthur Nádas; Michael W Cho; Michael L Dustin; Scott C Kachlany
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

3.  International network for comparison of HIV neutralization assays: the NeutNet report.

Authors:  Eva Maria Fenyö; Alan Heath; Stefania Dispinseri; Harvey Holmes; Paolo Lusso; Susan Zolla-Pazner; Helen Donners; Leo Heyndrickx; Jose Alcami; Vera Bongertz; Christian Jassoy; Mauro Malnati; David Montefiori; Christiane Moog; Lynn Morris; Saladin Osmanov; Victoria Polonis; Quentin Sattentau; Hanneke Schuitemaker; Ruengpung Sutthent; Terri Wrin; Gabriella Scarlatti
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

4.  An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma.

Authors:  Chiyu Zhang; Yunyun Chen; Kunlong Ben
Journal:  BMC Infect Dis       Date:  2003-12-23       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.